Scoop: J&J confirms that the FDA put AML drug on complete hold

J&J tells Endpoints News that a bispecific antibody it is partnered on with Genmab for acute myeloid leukemia has been put on clinical hold after patients in the trial suffered serious adverse events.

The drug, JNJ-63709178, targets both CD3 and CD123 and was in an early stage study when the hold was instituted, forcing investigators to suspend patient recruitment, according to the web site. The complete hold, which should stop dosing, followed.

A spokesperson for J&J confirmed the news, but declined to say just what adverse events were seen in the study.

“Janssen R&D temporarily suspended the study on Aug 8; the FDA put it on complete clinical hold effective Aug 16,” says the company spokesperson.  “We’re working with the FDA now to address recommended changes to the study.  At this point, we don’t have any additional details to share.  We’re hoping to resume the study with appropriate guidance from the FDA.”

News of the clinical hold was first raised in a tweet from Evaluate Pharma’s Jacob Plieth.

Get Endpoints News in your inbox

Newsletters for those who discover, develop, and market drugs. Enjoy the news with the story intact — entire articles in your inbox, no clicks required. Join 12,000+ biopharma pros who read Endpoints News every day. Free subscription.


Subscribe to Endpoints

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy